GSK-208355/125 (APV-125)

A phase III, open, multicenter study of the safety of Infanrix® when administered as a booster dose at 15 to 18 months of age following primary immunization in studies 217744/084 and 217744/085 (Subjects from DTaP-HepB-IPV-084 and DTaP-HepB-IPV-085)
Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed
208355/125 (APV-125)
Acellular pertussis; Diphtheria; Tetanus
Phase 3
An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2013